State-Backed Capital Inflates Chinese Neurotech Valuations as Shanghai Unicorn Files for Insolvent Star Market Listing

China’s aggressive, state-directed campaign to establish global dominance in frontier biotechnology has hit the public markets, exposing the raw financial strains of a sector heavily insulated from standard commercial metrics. Neuracle Technology (Shanghai) Co., a prominent local neurotechnology startup, has formally filed for an initial public offering on Shanghai’s tech-focused Star Market. The company is seeking to raise 2.5 billion yuan, or approximately US$345 million, in a bid to crown itself China’s first pure-play, publicly traded brain-computer interface (BCI) enterprise. The prospectus, officially accepted by the Shanghai Stock Exchange, provides a rare, unvarnished look at the internal balance sheets of…